Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies
Victor J. Dzau1, Ruediger C. Braun-Dullaeus2
& Daniel G. Sedding2
1
Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA
2
Department of Medicine, Giessen University, Giessen, Germany vdzau@partners.org
In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention, as well as to the formation of the fibrous cap that provides stability to the plaque. The VSMC can undergo a proliferative response that underlies the development of in-stent restenosis, bypass graft occlusion and transplant vasculopathy. Although the benefit/risk of therapeutic inhibition of VSMC proliferation in atherosclerosis is unclear, experimental and human evidence strongly suggests the therapeutic potential of antiproliferative therapy for in-stent restenosis, bypass graft failure and other vascular proliferative disorders.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
